Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 19/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.89 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031929 | 0.95 | CHRM1 (0.98) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7615829 | 0.94 | CHRM1 (0.89) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL4029826 | 0.94 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL4031351 | 0.93 | CHRM1 (0.97) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL4035543 | 0.91 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7900811 | 0.90 | CHRM4 (0.97) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6906658 | 0.89 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6913174 | 0.88 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL4030575 | 0.87 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6915951 | 0.87 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | claimed |
| US-5919805-A | 3-OXY- OR THIO-DERIVATIVES OF 1,2,5-OXADIAZOLES OR 1,2,5-THIADIAZOLES; TREATMENT OF ALZHEIMER'S DISEASE, SEVERE PAINFUL CONDITIONS AND GLAUCOMA. | NOVO NORDISK A/S (DK) | 1999-07-06 | — | — | US | claimed |
| EP-0866702-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-09-30 | — | — | EP | claimed |
| WO-1997020556-A9 | METHOD FOR TREATING PAIN | — | 1997-10-02 | — | — | WO | claimed |
| WO-1997020556-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| WO-1996013168-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | claimed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| EP-0544756-A1 | 1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-09 | — | — | EP | claimed |
| WO-1992003430-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| EP-0709094-B1 | Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety | LILLY CO ELI (US) | 2000-04-05 | — | — | EP | disclosed |
| EP-0709095-B1 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0866702-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5708014-A | SUBSTITUTED TETRAHYDROPYRIDINYL-1,2,5-OXADIAZOLES OR THIADIAZOLES | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997020556-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996013168-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
| WO-1996013167-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0709094-A2 | Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0709095-A2 | Method for treating anxiety using a tetrahydropyridine or azabicyclic oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5488056-A | 1,2,5-THIADIAZOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM1 8/4885CHRM4 2/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.